KRAS and adenocarcinoma: In 30% of adenocarcinomas, mutation of the KRAS proto-oncogene is the driving force behind oncogenic transformation, and similar mutations are found to a lesser extent (about 5%) in the squamous-cell carcinoma subtype [25].